Real-World Data for Medical Devices

Build the Evidence Before Launch. Prove the Value After.

Connect the detail of patient care with the long view of device outcomes. The Inovalon and OMNY Health Linked Closed Claims and EHR Dataset gives device teams one patient-level record of primary source closed claims and EHR data, from pre-commercial planning through every year on the market.

Whether you are planning a device launch or proving value after one, the right real-world evidence (RWE) strategy needs to be in place from the start.

Download our checklist covering the six questions to help you choose the right data partner.

Get the Checklist

Complete the form and we will send the checklist to your inbox.

By submitting, you agree to our Terms of Use and Privacy Policy. We value your privacy.

Thank you. The checklist is on its way to your inbox. In the meantime, talk to an expert about your device question.

Overview

See How Your Device Impacted the Full Patient Journey

The Inovalon and OMNY Health Linked Closed Claims and EHR Dataset joins two primary sources at the patient level. Inovalon primary source closed claims show what happened before and after your device was used, across commercial, Medicare Advantage, and Medicaid coverage. OMNY Health EHR data adds the clinical and device detail behind that use. Together, where linkage and attribution are available, they show the baseline before your device and what changed after it.

Select any point on the journey to see what each source captures.

Inovalon primary source closed claims

OMNY Health EHR data and clinical notes

Both

Payer coverage: Commercial

Payer transition

Medicare Advantage

Before Device Use

Device Use

After Device Use

Capture varies by device category, care setting, health system, and payer coverage. We characterize completeness, linkage, and enrollment continuity for your cohort before analysis begins.

By the Numbers

246M+
Covered Lives in Inovalon Primary Source Closed Claims
175M+
Patient Lives in OMNY Health Structured EHR Data
7B+
Clinical Notes

Inovalon and OMNY Health Linked Closed Claims and EHR Dataset2

Evidence by Team

What the Linked Dataset Delivers for Each Team

Each team brings a different evidence question, and the same linked dataset answers all of them.

Launch With the Benchmark Already Built

When a device category is new, the comparison group has to be built. Linked claims and EHR data define the standard of care pathway, its timing, and its outcomes before your trial reads out, so comparators and sample-size assumptions rest on observed care.

Talk to an Expert

Trial feasibility.

Eligible patients, event rates for sample size, and the facilities and physicians doing the procedure today, with facility type and setting from the EHR side.

Standard of care benchmarks.

Complication, reintervention, and readmission rates, plus the utilization and cost that go with them, for endpoint and comparator planning.

The current care pathway.

Who is treated today, how long they wait from diagnosis to intervention, and what happens without your device.

Build a Device-Value Story You Can Defend

Payers cover a device when it improves outcomes over standard of care at an acceptable cost. Showing that means following patients well past the procedure to capture revisions, readmissions, escalation to further treatment, and cost of care. Closed claims provide that longitudinal view, and linking them to EHR data adds the clinical detail, such as disease severity, labs, and procedure specifics, needed to compare like patients and attribute differences to the device.

Talk to an Expert

Multiyear outcomes.

Reintervention, revision, readmission, and treatment escalation across observed payers and care settings.

Cost of care.

Paid amounts, pharmacy and medical utilization, and site of care from primary source closed claims across commercial, Medicare Advantage, and Medicaid members.

Risk adjustment.

Comorbidity burden, labs, vitals, and documented severity from the EHR side, so the comparison holds up.

Postmarket Evidence That Keeps Pace With Your Obligations

Follow observed safety events, reinterventions, and care pathways after discharge and across insurance changes, with a monthly refresh and the lineage documentation your reporting requires.

Talk to an Expert

Device-level attribution.

Manufacturer, brand, and model information where captured, so the event ties back to the device that was used.

Rates with a real denominator.

Enrollment history shows how many patients were observed and for how long, so explant, revision, and infection rates are built on multiyear follow-up of a known population.

Clinical variables that do not code.

Severity, functional status, and documented complications live in the clinical notes, and the notes arrive as notes, so your team constructs its own phenotypes.

See Where Opportunity Is Growing

Commercial teams need a fast, broad read on where procedures, devices, and standards of care are moving and which accounts deserve attention first. Claims-based intelligence shows volume, site-of-care shifts, patient flow, and the providers and facilities worth a visit. EHR adds provider and patient sentiment and exploratory insights for label expansion.

Talk to an Expert

Volume and whitespace.

Procedure activity and label expansion opportunities across payer segments, providers, facilities, and geographies.

Site-of-care dynamics.

Shifts between inpatient, outpatient, ambulatory, and home settings, with facility-level attribution where available.

Account and territory prioritization.

Provider and facility NPI from the claims side for target selection, adoption tracking, and launch planning.

Regulatory Landscape

Evidence Planning Is Moving Upstream

FDA’s December 2025 device guidance recognizes EHR data and claims, alone or combined, as sources of real-world evidence when they fit the regulatory question, and asks sponsors for more detailed documentation of relevance, reliability, and study design.3 CMS has proposed carrying the same kind of evidence into coverage decisions for certain Breakthrough Devices.4 FDA has also drafted guidance on nonclinical testing, clinical data, and labeling for certain robotically assisted surgical devices.5 In practice, the evidence plan starts earlier, and the data behind it has to hold up to scrutiny.

The FDA guidance is nonbinding, RAPID is a proposal awaiting a final notice, and FDA evaluates each submission case by case. Real-world evidence will not fit every device or question, so we document provenance and lineage with every study and set scope with you at the start.

Dec. 18, 2025

FDA finalizes the device RWE guidance

April 2026

CMS proposes the RAPID coverage pathway

Sept. 2026

FDA drafts surgical robotics guidance

Resources

MedTech Evidence Insights From Our Experts

Explore expert articles, blog posts, and on-demand webinars on building device evidence that holds up from launch planning through postmarket.

FAQ

Questions Evidence Teams Ask Us

Claims alone usually cannot, because billing codes identify a procedure, supply, or technology category. In the linked dataset, OMNY Health EHR data adds device information, including manufacturer, brand, and model where captured, which supports device-level attribution for many device records. Coverage varies by device and care setting, so we confirm what is available for your device before a study is scoped.

Yes. Every device has a baseline before use, a moment of use, and a period that follows, and the linked dataset covers all three. For a test, the evidence question is whether the result changed treatment and outcomes. For therapy or monitoring, it is whether patients persisted, avoided acute events, and used less care across payers. How precisely your device can be identified in the data does vary by product, and we start every conversation there.

For as long as a patient stays in observed coverage, including through transitions between commercial, Medicare Advantage, and Medicaid plans. That follow-up supports multiyear measurement of revision, explant, readmission, persistence, and cost of care. We characterize enrollment continuity and observation time for your cohort before analysis begins.

No. The December 2025 guidance is nonbinding and presents FDA’s recommendations, in “should” language, although a recommendation may relate to an underlying statutory or regulatory requirement. FDA evaluates the relevance and reliability of real-world data against the specific regulatory question, case by case. A submission rests on documented provenance, curation, cohort definitions, and analytic design, and we provide that documentation with every study.

Let’s transform healthcare together.

Questions? Call (888) 895-2649. Bring us one device question and we will walk through what the linked dataset can answer.

Talk to an Expert
  1. Inovalon Outcomes and Evidence Solutions Overview, Inovalon internal reporting, September 2026. [Figures require Barton Jones sign-off before publish.]
  2. Inovalon and OMNY Health Linked Closed Claims and EHR Dataset, as published on inovalon.com/products/data-cloud/linked-datasets/, 2026. [Figures require Barton Jones sign-off before publish.]
  3. “Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices,” Final Guidance, U.S. Food and Drug Administration, Dec. 18, 2025. Supersedes the Aug. 31, 2017, guidance of the same name. [Add URL.]
  4. “Regulatory Alignment for Predictable and Immediate Device Coverage (RAPID),” proposed procedural notice, Centers for Medicare and Medicaid Services, April 2026. Public comment period closed Oct. 13, 2026. [Add URL.]
  5. Draft guidance on nonclinical testing, clinical data, and labeling for certain robotically assisted surgical devices, U.S. Food and Drug Administration, September 2026. Comments due Nov. 24, 2026. [Add exact title and URL.]